NCT07087431View on ClinicalTrials.gov

Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health

NANot yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

August 15, 2026

Study Completion Date

August 15, 2027

Conditions
Coronary Artery Disease
Interventions
BEHAVIORAL

Immediate disclosure of non-high CAD PRS

Participants receive their non-high CAD PRS result as soon as it is available after genotyping.

BEHAVIORAL

Deferred Disclosure of non-high CAD PRS

Participants receive their non-high CAD PRS result after completion of the 12 month follow up period.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Massachusetts General Hospital

OTHER

NCT07087431 - Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health | Biotech Hunter | Biotech Hunter